Organisation paid for research Program year 2025 Source: CMS Open Payments

York Clinical Research LLC

Neither a doctor nor a teaching hospital

Research payments

$699,372

117 payments

Through program year 2025, York Clinical Research LLC is reported as receiving $699,372 in research payments, across 117 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $22,793 8
2024 Research $38,901 7
2023 Research $59,643 13
2022 Research $119,433 10
2021 Research $51,743 8
2020 Research $135,036 22
2019 Research $271,823 49

Breakdown

Who paid Research payments · program years 2019–2025
  1. Sanofi US Services Inc. $131,383 25 payments
  2. Novo Nordisk AS $111,927 24 payments
  3. Novartis Pharmaceuticals Corporation $97,037 4 payments
  4. Moderna TX, Inc. $87,707 26 payments
  5. Vertex Pharmaceuticals Incorporated $76,329 4 payments
  6. Amgen Inc. $72,587 19 payments
  7. Boehringer Ingelheim Pharmaceuticals, Inc. $42,851 3 payments
  8. Akcea Therapeutics, Inc. $42,288 4 payments
  9. Lexicon Pharmaceuticals, Inc. $21,127 1 payment
  10. Ionis Pharmaceuticals, Inc. $9,520 4 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age $87,707 26 payments
  2. A Phase 2/3 Adaptive, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of VX-147 in Subjects Aged 18 Years and Older With APOL1-mediated Proteinuric Kidney Disease $76,329 4 payments
  3. A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Efpeglenatide on Cardiovascular Outcomes in Type 2 Diabetes Patients at High Cardiovascular Risk $65,587 10 payments
  4. A Randomized Double-Blind, Placebo-Controlled, Multicenter Trial Assessing the Impact of Lipoprotein (A) Lowering With Tqj230 on Major Cardiovascular Events in Patients With Established Cardiovascular Disease $64,827 1 payment
  5. Nn1250-4252 $47,952 5 payments
  6. Exercise capacity study in HFpEF $34,809 2 payments
  7. Galactic-Hf $31,680 3 payments
  8. Ex9536-4388 $30,816 10 payments
  9. A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Efpeglenatide on Cardiovascular Outcomes in Type 2 Diabetes Patients at High Cardiovascular $30,015 1 payment
  10. Multi-center cross-sectional epidemiological study to characterize the prevalence and distribution of lipoprotein(a) levels among patients with established cardiovascular disease $28,210 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record